Pure Large Cell Neuroendocrine Carcinoma of Ovary: A Rare Clinical Entity and Review of Literature

Table 1

Clinicopathologic, treatment modality, and followup of women with pure large cell neuroendocrine tumour of ovary.

S. no.	Authors	Age/present.	Associated component	Site/laterality	Stage	Treatment modality	Followup
(1)	Behnam et al. [1]	27/pelvic mass	None	11 cm, left	Ic	LSO/omentectomy/; chemotherapy	NED 10 m
(2)	Lindboe [2]	64/abdominal discomport	None	14 cm, right	Ia	TAH/BSO/omentectomy/; chemotherapy	NED 9 m
(3)	Dundr et al. [3]	73/NA	None	9 cm, left	N/A	N/A	N/A
(4)	Aslam et al.; [4]	76/abdominal pain	None	35, left	N/A	TAH/BSO/OMT	Died soon
(5)	Tsuji et al. [5]	46/abdominal distension	None (focal squamous differentiation)	12, right	N/A	TAH/BSO/OMT	Died in 4 m
(6)	Japan Oshita et al. (4 cases) [6]	42–81/N/A	Mixed epithelial carcinoma-3 cases,; 1-none	N/A	Ic; IIc; IIIC; IV	N/A, chemotherapy—paclitaxel and carboplatin	Died in 2 m; Rest with or without recc-32–64 mo
(7)	Present case	40/abdominal dist., fever, itching	none	Bilateral ovarian; 7 cm, Right; 15 cm, Left	IIIc	BSO/TD/TO/ /PALND/; Bladder and sigmoid colon deposit excision + 5 cycles of etoposide (mesna) and cisplatin	NED-6 m

AWD: alive with disease; TAH: total hysterectomy, RSO: right salpingo-oophorectomy; BSO: bilateral salpingo-oophorectomy; LSO: left salpingo-oophorectomy; N/A: no information available; NED: no evidence of disease; NOS: not otherwise specified; DOD: dead of disease; m: months; y: years.